SIEMENS HEALTHINEERS Y IUL SA, una nueva alianza para combatir la COVID-19

The IUL’s reader, so-called iPeak®, capture, and process the image of the test guaranteeing the objectivity of the interpretation and increasing the sensitivity of the reader of rapid tests

 

Partners
foto
Barcelona

IUL SA and Siemens Healthineers Netherlands in collaboration to deliver qualitative results to support conducting large-scale COVID-19 studies. On the 13th of October Siemens Healthineers launched its antigen rapid test to detect the virus SARS-CoV-2 in 15 minutes which, together with the technology of IUL SA, allows monitoring the state of the pandemic in real-time, sending the results to the health care centers involved in the fight against COVID-19.

The IUL’s reader, so-called iPeak®, capture, and process the image of the test guaranteeing the objectivity of the interpretation and increasing the sensitivity of the reader of rapid tests. Its advanced optical and image analysis system delivers qualitative results, at the same time the reader will help in the traceability of Covid-19 cases sending the results in real-time. 

Pieter van der Meijs, Sales Director of Laboratory Diagnostics at Siemens Healthineers in The Netherlands highlights the sensitivity of the iPeak® and how IUL SA has been fast flexible and accurate, being the perfect ally in providing a complete solution to support high throughput test facilities in the Netherlands. Vicenç Font, CEO at IUL SA, underlies the commitment and determination of Siemens Healthineers from the first moment that the project began, being the reader a key piece to combat this pandemic.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. Further information is available at www.siemens-healthineers.com.

IUL SA, LEADER IN INDUSTRY 4.0 AND THE FIGHT AGAINST COVID-19

IUL SA, with the headquarters in Barcelona, designs, produces, and marketed solutions for microbiology lab automation since 1987. A landmark in Industry 4.0, his objective is to enable a more comfortable, and safer microbiological control for the industry and to provide devices for in-vitro diagnostics in the field of human and animal health. Thanks to its R&D investment, IUL SA has developed entirely in Barcelona this innovative reader that is already marketed in countries such as the USA, India, Italia, Belgium, the Netherlands, Singapore, or Taiwan, among others

Contact information

Nal3 Comunicació - 932 388 080

Ariadna Morales ariadna@nal3.com 

 

Attached files
Tags
Coronavirus
Innovación
Biofarmacéutica
Test